Les travaux que nous finançons (en anglais seulement)

Funded projects
1 200+
Men's Health Partners
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Movember PhD Studentships in Bioinformatics

Movember Funding to Date

GBP 453,674

What we seek to achieve

To train a new generation of researchers with expertise in bioinformatics and prostate cancer in order to make most benefit from new big data sources. We will do this by funding PhD studentships, embedding those students within top prostate research groups with expertise in bioinformatics.

United Kingdom
Implemented by
Prostate Cancer UK
Project start date
December 2015
Project Status
In Progress

About the project

We believe that some of the most important research in the next ten years will require and generate large quantities of complex data. Expertise in obtaining, manipulating and analysing those data will be dependent on expert bioinformaticians with training and experience in prostate cancer that complements their mathematical training.

Understanding why multiple prostate cancers appear together

We’ve granted £83,979 to Dr Daniel Brewer at the University of East Anglia to train a PhD student to analyse data that might allow us to make sense of the mysterious prostate cancer field effect. This could have major implications for which treatments men should choose and also, one day, for preventing the disease.
Building a database of prostate cancer genetic information 

Professor Johann de Bono and his PhD student will gather and analyse the masses of genetic data available from prostate cancer patients’ biopsy and blood samples to work out which treatments, and which clinical trials, might work best for them.

Making sense of big data on small molecules 

Dr Hector Keun and his PhD student will unlock the power of microRNAs to distinguish aggressive cancers from low-risk ones and to tell us which is likely to be the best treatment for an individual man’s cancer

Using computers to predict treatment response 

Dr Crispin Miller will train a PhD student to develop computer models to predict how men with advanced prostate cancer will respond to treatment. Ultimately this work will help us to get better at matching the treatment given to an individual man’s cancer.


These awards were made according to Prostate Cancer UK’s independently audited processes including open competition through a call for proposals, full written peer review by international, non-conflicted experts and finally funding recommendations provided by an expert panel drawn from Prostate Cancer UK’s Research Advisory Committee.

Page 1 of 22